Annex to Report of the Coordinating Group

44th Board Meeting

GF/B44/10 – Annex 1
11-12 November 2020 (Virtual Meeting)

Board Information

Annex 1 to GF/B44/10, providing overview of decisions taken by the three committees between the 43rd and 44th Board Meetings.
Annex 1 to GF/B44/10:

Committee Decisions adopted between the 43rd and 44th Board meetings
(15 May 2020 – 11 November 2020)

---

Decision Points approved by the Audit and Finance Committee between the 43rd and 44th Board Meetings

<table>
<thead>
<tr>
<th>DP Ref. No.</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>GF/AFC13/DP01</td>
<td>Provident Fund Investment Strategy</td>
</tr>
<tr>
<td>GF/AFC13/DP02</td>
<td>External Audit Plan</td>
</tr>
<tr>
<td>GF/AFC13/EDP01</td>
<td>Approval of Available Sources of Funds for the C19RM Mechanism</td>
</tr>
<tr>
<td>GF/AFC13/EDP02</td>
<td>Approval of the 2020 Interim Financial Report</td>
</tr>
</tbody>
</table>

13th AFC Meeting, 02-03 July 2020

14th AFC Meeting, 08-09 October 2020

---

13th Audit and Finance Committee Meeting Decision Points

**Decision point: GF/AFC13/DP01: Approval of Amended Provident Fund Investment Strategy**

1. The Audit and Finance Committee has reviewed the presentation of the Strategic Asset Allocation study of the Global Fund Provident Fund (the “GFPF”), including the methodology, assumptions and correlations as outlined in the Annex to GF/AFC13/02.

2. Accordingly, under the authority delegated by the Board pursuant to decision point GF/B20/DP18 (November 2009), the Audit and Finance Committee approves the amended investment strategy set forth in GF/AFC13/02, which includes the asset classes, asset allocations and risk profile, and acknowledges the current set-up and financing remains unchanged in accordance with the GFPF Constitutional Declaration and Benefits Rules.

3. This decision supersedes the GFPF investment strategy approved by the Audit and Finance Committee pursuant to decision point GF/AFC03/DP01 (March 2017).
**Decision Point: GF/AFC13/DP02: Approval of the External Audit Plan**

The Audit and Finance Committee approves the External Audit Plan for the year ending 31 December 2020, as set forth in GF/AFC13/03, based upon its review of such plan and discussion with KPMG SA as independent external auditor.

**Decision point: GF/AFC13/EDP01: Approval of Available Sources of Funds for the C19RM Mechanism**

1. The Audit and Finance Committee recognizes the Board decision point GF/B42/EDP11 (April 2020), creating a temporary COVID-19 response mechanism (C19RM) and approving the mobilization of additional resources from private and public donors for C19RM.

2. Based on its review and discussion of the Secretariat’s analysis of sources and uses of funds, as presented in GF/AFC13/ER01 Part A, the Audit and Finance Committee:
   
   a. approves the additional amount of US$ 165 million as available sources of funds;
   
   b. acknowledges that the additional amount of US$165 million will be applied to C19RM pursuant to Board decision point GF/B42/EDP11; and
   
   c. accepts that the total available sources of funds for C19RM shall accordingly be US$ 665 million.

*Budgetary implications (included in, or additional to, OpEx budget): N/A*

**Decision point: GF/AFC13/EDP02: Approval of the 2020 Interim Financial Report**

The Audit and Finance Committee authorizes the issuance of, and therefore approves, the Global Fund’s 2020 Interim Financial Report, which includes the Interim Condensed Financial Statements as at and for the period ended 30 June 2020 that have been reviewed by KPMG SA, as set forth in Annex 1 to GF/AFC13/ER3.

*Budgetary implications (included in, or additional to, OpEx budget): N/A*
Decision Point GF/AFC14/DP01: Recommendation on the 2021 Work Plan and Budget Narrative and the 2021 Operating Expenses Budget

1. The Audit and Finance Committee (the “AFC”):
   a. Acknowledges its review and discussion of the 2021 Work Plan and Budget Narrative, as set forth in GF/AFC14/07-Part A, and decides to recommend it to the Board for approval at its forty-fourth meeting in November 2020;

   b. Decides to recommend the 2021 Operating Expenses Budget, in the amount of US$315 million, as set forth in GF/AFC14/07– Part B, to the Board for approval at its forty-fourth meeting in November 2020;

   c. Notes its approval of including the Office of the Inspector General’s 2021 budget, in the amount of US$14.90 million, in the 2021 Operating Expenses Budget (GF/AFC14/DP02); and

   d. Acknowledges constraints in projected remaining funds available for 2022 OPEX Budget and requests the Secretariat to submit a revised 3-year budget ceiling, no later than fifteenth meeting of the AFC.

2. Accordingly, the AFC recommends the following decision point to the Board for approval at its forty-fourth meeting in November 2020:

Decision Point: GF/44/DPXX: 2021 Work Plan and Budget Narrative and the 2021 Operating Expenses Budget

Based on the recommendation of the Audit and Finance Committee, the Board approves the following:

1. 2021 Work Plan and Budget Narrative, as set forth in GF/B44/XX; and

2. The 2021 Operating Expenses Budget in the amount of US$315 million, as set forth in GF/B44/XX (the “2021 OPEX Budget”), which includes US$14.90 million for the Office of the Inspector General’s 2021 operating expenses.

Decision Point: GF/AFC14/DP02: Approval of the OIG’s 2021 Work Plan, Budget and Key Performance Indicators

The Audit and Finance Committee (the “AFC”):

a. approves the 2021 work plan of the OIG set forth in Section VI of GF/AFC14/05;

b. approves the inclusion of the OIG’s 2021 operating expenses budget, in the amount of US$14.9 million, in the 2021 Operating Expenses Budget of the Global Fund (the “2021 OPEX Budget”) to be recommended by the AFC to the Board for approval at the forty-fourth Board meeting in November 2020;

c. approves the 2021 Key Performance Indicators for the OIG set forth in Section VI of GF/AFC14/05.
### Decision Points approved by the Ethics and Governance Committee between the 43rd and 44th Board Meetings

<table>
<thead>
<tr>
<th>DP Ref. No.</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13th EGC Meeting, 29-30 June 2020</strong></td>
<td>No decisions taken</td>
</tr>
<tr>
<td><strong>14th EGC Meeting, 06-07 October 2020</strong></td>
<td></td>
</tr>
<tr>
<td>GF/EGC14/DP01</td>
<td>Approval of the 2021 Ethics Function Work Plan and Associated Operating Expenses Budget</td>
</tr>
<tr>
<td>GF/EGC14/DP02</td>
<td>Performance Evaluation Process of the Ethics Officer</td>
</tr>
</tbody>
</table>

### 14th Ethics and Governance Committee Meeting Decision Points

**Decision Point: GF/EGC14/DP01: Approval of the 2021 Ethics Function Work Plan and Associated Operating Expenses Budget**

1. The Ethics and Governance Committee (the “EGC”) approves the 2021 Work Plan for the Ethics Function, as presented in the document GF/EGC14/DP01.

2. Additionally, the EGC recommends to the Audit and Finance Committee the 2021 Operating expenses budget associated with the work plan, in the amount of USD 1,857,000 as set forth in this document, for inclusion in the Global Fund’s overall 2021 operating expenses budget that will be presented to the Board for approval at its November 2020 meeting. In doing so, EGC notes that USD 1,219,700 funding for the implementation of the Code of Conduct for CCM Members.

**Decision Point: GF/EGC14/DP02: Performance Evaluation Process of the Ethics Officer**

The Ethics and Governance Committee (“EGC”):

i. Notes its responsibility under the Terms of Reference of the Global Fund Ethics Officer (GF/B33/EDP14) to jointly conduct with the Executive Director the performance evaluation of the Ethics Officer, with input from the Board Leadership and the Inspector General;

ii. Notes the overview of the Ethics Officer annual performance evaluation process as set out in document GF/EGC07/Confidential Document, as such process may be updated to align with the Secretariat’s performance management framework in effect at the time of such evaluation;

iii. Delegates to Suomi Sakai and Mohamed Chakroun (the “EGC Delegates”) the authority to act on behalf of the EGC in conducting the Ethics Officer performance assessment jointly with the Executive Director and requests them to periodically report back to the EGC on the process.

**Budgetary implications:** The outcome of the evaluation process may lead to a salary increase for the Ethics Officer, which is already part of the Opex budget to be approved annually by the Board.
## Decision Points approved by the Strategy Committee between the 43rd and 44th Board Meetings

<table>
<thead>
<tr>
<th>DP Ref. No.</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13th SC Meeting, 30 June-01 July 2020</strong></td>
<td></td>
</tr>
<tr>
<td>GF/SC13/EDP01</td>
<td>Appointment of the Strategy Committee Focal Point to the TERG</td>
</tr>
<tr>
<td><strong>14th SC Meeting, 05-06 October 2020</strong></td>
<td></td>
</tr>
<tr>
<td>GF/SC14/DP01</td>
<td>Recommendation of Additional Funding to Address the Health Crisis in Venezuela in 2021.</td>
</tr>
<tr>
<td>GF/SC14/DP02</td>
<td>Revisions for Key Performance Indicators</td>
</tr>
<tr>
<td>GF/SC14/DP03</td>
<td>Dates and Format of the 6th Partnership Forums</td>
</tr>
<tr>
<td>GF/SC14/DP04</td>
<td>Approval of wambo.org pilot reporting metrics</td>
</tr>
<tr>
<td>GF/SC14/DP05</td>
<td>Recommendation on extending the timeline for including COVID-19 products in the wambo.org pilot</td>
</tr>
<tr>
<td>GF/SC14/DP06</td>
<td>TERG Work Plan and Budget 2021 (amended)</td>
</tr>
</tbody>
</table>

### 13th Strategy Committee Meeting Decision Points

**Decision Point: GF/SC13/EDP01: Appointment of the Strategy Committee Focal Point to the TERG**

The Strategy Committee decides to appoint Kieran Daly to serve as Strategy Committee focal point on matters of the TERG from the date hereof and for the duration of his term as a Strategy Committee member or until a replacement focal point is appointed.

*Budgetary implications: none.*
## Decision Point: GF/SC14/DP01: Recommendation of Additional Funding to Address the Health Crisis in Venezuela in 2021.

Acknowledging the Board’s approval under GF/B39/DP04 to consider potential extraordinary funding for non-eligible countries experiencing health crises, the Strategy Committee:

Acknowledges the Board’s approval under GF/B39/EDP11 and GF/B41/EDP14 of a US$ 5,000,000 investment for 2019 to support the procurement of critical HIV health products for Venezuela and a US$ 6,000,000 investment for 2020 to support the procurement of critical HIV, TB and malaria health products;

Confirms that the Secretariat’s analysis of the continuing health crisis in Venezuela, as described in GF/SC14/02, which was developed in consultation with partners and civil society and submitted to the Strategy Committee in accordance with GF/B39/DP04, meets the criteria described in GF/B39/03 – Revision 1; and

Determines that the potential impact of the proposed new investment of US$ 6,000,000, as described in Annex 1 of GF/SC14/02, justifies funding the investment from funds that would otherwise be available for investment in prioritized areas of unfunded quality demand in eligible countries pursuant to GF/SC04/04 – Revision 2.

2. Accordingly, the Strategy Committee recommends the following decision point to the Board for electronic approval:

**GF/BXX/EDPXX Approval of Additional Funding to Address the Health Crisis in Venezuela**

The Board:

1. Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;

2. Acknowledges the new proposal for exceptional funding in 2021 presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;

3. Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B44/XX and Annex 1;

4. Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B44/XX and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B44/XX and Annex 1;

5. Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 6,000,000, for the year 2021, to support the procurement of critical HIV & TB health products for Venezuela and social monitoring of the investment; and

6. Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.

**Budgetary implications:** US$ 6,000,000, funded through available sources of funds identified by the Audit and Finance Committee under GF/AFC12/DP01.
**Decision Point: GF/SC14/DP02: Revisions for Key Performance Indicators**

Based on its review and discussion of the proposal presented by the Secretariat, the Strategy Committee (the “SC”) recommends that the Board approve revisions for Key Performance Indicators 3, 5, 6a, 6b and 9b as set forth in GF/SC14/DPXX.

Accordingly, the SC recommends the following decision point to the Board for approval at its 44th Meeting in November 2020:

GF/B44/DPXX: Revisions for Key Performance Indicators

Based on the recommendation of the Strategy Committee, the Board approves the revisions for Key Performance Indicators 3, 5, 6a, 6b and 9b as presented in GF/B44/DPXX.

*This decision has no budgetary implications.*

**Decision Point: GF/SC14/DP03: Revised Dates and Format for the 6th Partnership Forums for the Development of the Next Global Fund Strategy**

Based on the recommendation of the Secretariat, as presented in GF/SC14/16, and due to the continued disruptions and safety concerns posed by the COVID-19 pandemic, the Strategy Committee:

1. Approves, through authority delegated to it by the Board in GF/B42/EDP12, the following revised dates for the 6th Partnership Forums for the development of the next Global Fund strategy, which will be held in a virtual format as detailed in GF/SC14/16:
   
i. Eastern Europe and Central Asia & Latin America and the Caribbean, 9-11 February 2021
   ii. Africa, 17-19 February 2021
   iii. Asia, 3-5 March 2021

2. Due to the evolving nature of the COVID-19 pandemic and the tight timelines for convening Partnership Forums (a) delegates to the Secretariat flexibility to postpone any of the Partnership Forums and (b) commits to approve, on an expedited basis, further changes to Partnership Forum locations, dates and/or formats.

*Budgetary implications: associated costs will be covered by OPEX.*

**Decision Point: GF/SC14/DP04: Approval of Metrics for Bi-Annual Reporting of wambo.org Pilot**

The Strategy Committee recalls the Board instructing the Secretariat, pursuant to GF/B42/DP05, to undertake consultations early in 2020 and establish metrics for the biannual reporting on progress of the wambo.org pilot to be approved by the Strategy Committee.

Accordingly, following the outcome of the consultations held in 2020, the Strategy Committee approves the metrics, as presented in GF/SC14/12.

*Budgetary implications (included in, or additional to, OPEX budget): none.*
**Decision Point: GF/SC14/DP05: Recommendation on Extending the Timeline for Including COVID-19 Products in the wambo.org Pilot**

1. The Strategy Committee (“SC”):

   a) Recalls GF/B43/EDP07 where the Board (i) decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and (ii) specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the SC;

   b) Acknowledges its review and discussion of the proposal to change the period during which purchase orders for such non-Global Fund financed transactions for COVID-19 products may be issued to end on 31 May 2021, subject to the continued applicability of all other conditions and flexibilities set forth in GF/B43/EDP07;

   c) Decides to recommend the change in the end date of the period in which these flexibilities may be used to facilitate broader access to COVID-19 products to 31 May 2021, to the Board for approval at its 44th meeting.

2. Accordingly, the SC recommends the following decision point to the Board for approval at its 44th meeting:

   **Decision Point: GF/B44/DPXX: Extending the Timeline for Including COVID-19 Products in the wambo.org Pilot**

   The Board:

   Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee; and

   Based on the recommendation of the Strategy Committee, the Board approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org to 31 May 2021 and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.

   **Budgetary implications (included in, or additional to, OPEX budget):** The cost of additional licenses associated with the use of wambo.org will be absorbed within the Secretariat’s existing license packages, which currently include some unused licenses. If further licenses are needed, costs and options to cover these costs will be evaluated by the Secretariat. Costs relating to the expansion of the product catalogue to include COVID-19 products, which are already being incurred as a result of the creation of C19RM under GF/B42/EDP11, will be managed within the existing budget and will be incurred independently of this decision. There are no other anticipated budgetary implications at this time, as new buyer onboardings and transactions will be managed by existing staff.

1. The Strategy Committee (the “SC”) approves the Technical Evaluation Reference Group’s (the “TERG”) Annual Work Plan 2021, as presented in GF/SC14/09 – Revision 1, as part of the TERG Evaluation Plan 2017-2022, noting that the TERG will return to the SC, before the end of 2020, for specific approval of the use of the funds set aside for Independent Evaluation (USD 22 million) as part of catalytic investments for the 2020-2022 allocation period.

2. The SC acknowledges that this decision point does not preempt further discussion of a new differentiation of roles between the TERG and Secretariat on strategic evaluations nor the development of the M&E framework.

3. Accordingly, the SC acknowledges and recommends the 2021 TERG budget of USD 1.44 million, as outlined in GF/SC14/09 – Revision 1, which has been included in the Global Fund’s 2021 operating expenses budget will be submitted to the Board for approval at its November 2020 meeting, based on the recommendation of the Audit and Finance Committee.

Budgetary implications (included in OPEX budget): USD 1.44 million is included in OPEX.